HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
Focusing on microvascular disorders throughout the body, we have developed the world's first “vascular endothelial stem cells” as a cell-based therapeutic agent, providing a novel vascular regeneration treatment to reduce the risk of heart disease and dementia.
A drug discovery startup that uses proprietary technology to analyze molecular motion, uncovering previously untargeted disease-causing factors and developing therapeutic drugs. We conduct integrated research from basic studies to clinical development, aiming to create novel treatments.
Some children suffer from learning disabilities and experience difficulties in daily life due to poor eye movement, which makes it difficult to read and to play sports. We are developing an evidence-based system that uses eye tracking and eye movement indexing technologies to assess eye movements and provide training for children who are encountering these eyesight challenges. We are currently deploying this system in municipal consultation centers, elementary schools, and after-school day care centers.
A startup combining genome editing with smart land-based aquaculture to breed and produce high-value fish species using local resources. It aims to revitalize the fisheries industry and stabilize food supply, while contributing to lower environmental impact and regional revitalization.
